See more : Genus plc (GENSF) Income Statement Analysis – Financial Results
Complete financial analysis of Enzolytics Inc. (ENZC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enzolytics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SoldOut, Inc. (6553.T) Income Statement Analysis – Financial Results
- HMT (Xiamen) New Technical Materials Co., Ltd (603306.SS) Income Statement Analysis – Financial Results
- MAV Beauty Brands Inc. (MAV.TO) Income Statement Analysis – Financial Results
- Teamway International Group Holdings Limited (1239.HK) Income Statement Analysis – Financial Results
- Seneca Financial Corp. (SNNF) Income Statement Analysis – Financial Results
Enzolytics Inc. (ENZC)
About Enzolytics Inc.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.80K | 0.00 | 200.00K | 0.00 | 0.00 | 5.00K | 190.00K | 0.00 | 0.00 | 36.97K | 14.71K | 5.69K | 0.00 |
| Cost of Revenue | 22.09K | 22.09K | 16.96K | 16.96K | 16.96K | 16.81K | 741.20K | 18.75K | 19.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 30.71K | -22.09K | 183.04K | -16.96K | -16.96K | -11.81K | -551.20K | -18.75K | -19.22K | 36.97K | 14.71K | 5.69K | 0.00 |
| Gross Profit Ratio | 58.16% | 0.00% | 91.52% | 0.00% | 0.00% | -236.20% | -290.10% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 171.61K | 567.87K | 116.75K | 501.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.90M | 936.82K | 394.12K | 40.20K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.01M | 2.31M | 1.47M | 2.78M | 645.41K | 1.69M | 264.81K | 45.29K | 5.02M | 2.90M | 936.82K | 394.12K | 40.20K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.29M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.18M | 2.88M | 1.59M | 3.29M | 645.41K | 1.69M | 264.81K | 45.29K | 5.02M | 2.91M | 950.12K | 403.00K | 43.18K |
| Cost & Expenses | 2.20M | 2.90M | 1.61M | 3.30M | 662.37K | 1.71M | 1.01M | 64.04K | 5.04M | 2.91M | 950.12K | 403.00K | 43.18K |
| Interest Income | 2.00 | 60.00 | 91.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 27.72K | 37.32K | 37.33K | 177.30K | 118.82K | 50.99K | 61.73K | 21.92K | 24.62K | 68.95K | 34.38K | 28.64K | 21.64K |
| Depreciation & Amortization | 22.09K | 22.09K | 20.44K | 16.96K | 16.96K | 16.81K | 322.99K | 18.75K | 19.22K | 12.38K | 13.30K | 8.87K | 2.98K |
| EBITDA | -2.12M | -2.88M | -611.72K | -3.29M | 1.06M | -1.69M | 327.44K | -45.29K | -5.02M | -7.43M | -922.12K | -388.44K | 316.60K |
| EBITDA Ratio | -4,019.30% | 0.00% | -695.19% | 0.00% | 0.00% | -33,798.60% | -259.48% | 0.00% | 0.00% | -16,649.25% | -6,269.48% | -6,830.26% | 0.00% |
| Operating Income | -2.15M | -2.90M | -1.41M | -3.30M | -662.37K | -1.71M | -816.01K | -64.04K | -5.04M | -2.88M | -935.41K | -397.31K | -43.18K |
| Operating Income Ratio | -4,070.01% | 0.00% | -705.41% | 0.00% | 0.00% | -34,134.80% | -429.48% | 0.00% | 0.00% | -7,777.15% | -6,359.89% | -6,986.30% | 0.00% |
| Total Other Income/Expenses | -28.03K | -37.26K | 741.33K | -177.30K | 1.58M | -50.99K | 758.73K | -489.33K | -24.62K | -4.64M | -34.38K | -28.64K | -356.80K |
| Income Before Tax | -2.18M | -2.94M | -669.49K | -3.48M | 920.43K | -1.76M | -57.28K | -553.37K | -5.07M | -7.51M | -969.79K | 0.00 | -399.98K |
| Income Before Tax Ratio | -4,123.10% | 0.00% | -334.74% | 0.00% | 0.00% | -35,154.52% | -30.15% | 0.00% | 0.00% | -20,325.46% | -6,593.61% | 0.00% | 0.00% |
| Income Tax Expense | 2.00 | 2.00 | -2.00 | -4.00 | -4.00 | 0.00 | -4.00 | -3.78K | -19.28K | -3.22M | 0.00 | 28.64K | 378.44K |
| Net Income | -2.18M | -2.94M | -669.49K | -3.48M | 920.43K | -1.76M | -57.28K | -549.59K | -5.05M | -7.51M | -969.79K | -425.95K | -421.62K |
| Net Income Ratio | -4,123.10% | 0.00% | -334.74% | 0.00% | 0.00% | -35,154.52% | -30.15% | 0.00% | 0.00% | -20,325.46% | -6,593.61% | -7,489.85% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.04 | -541.66 | -256.63 | -118.91 | -155.29 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.04 | -541.66 | -256.63 | -118.91 | -155.29 |
| Weighted Avg Shares Out | 2.93B | 2.82B | 2.80B | 959.33M | 959.33M | 391.52M | 171.67M | 110.79M | 114.79M | 13.87K | 3.78K | 3.58K | 2.72K |
| Weighted Avg Shares Out (Dil) | 2.93B | 2.82B | 2.80B | 959.33M | 959.33M | 391.52M | 171.67M | 110.79M | 114.79M | 13.87K | 3.78K | 3.58K | 2.72K |
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator
FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT ALLEN, TX / ACCESSWIRE / September 18, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences, represented by Professor Tchorbanov...
Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences and Enzolytics, Inc. Execute Three Year Agreement
ALLEN, TX / ACCESSWIRE / September 9, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (" enzolytics.com ") (the "Company") announced today that the Company and the Stephan Angeloff Institute of Microbiology, Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences,...
Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells
ALLEN, TX / ACCESSWIRE / August 20, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that a study conducted at the Ministry of Health National Centre of Infectious and Parasitic Diseases in Sofia, Bulgaria concluded that inventor...
Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications
As well as Diabetes, Multiple Sclerosis and Other Diseases ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company and the Department of Immunology, Bulgarian Academy of Science...
Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.
Updates on Results of Litigation ALLEN, TX / ACCESSWIRE / July 29, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered into a 4 year Collaboration Agreement with Elimus, Ltd ("Elimus"), a Bulgarian company located...
Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release
ALLEN, TX / ACCESSWIRE / July 26, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ( enzolytics.com ) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to...
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2, "Inactivated...
Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology
ALLEN, TX / ACCESSWIRE / June 3, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") is thrilled to announce that the Company and Sagaliam Acquisition Corp ("SAGA") are negotiating a landmark investment of six million US dollars ($6,000,000). This investment...
Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment
ALLEN, TX / ACCESSWIRE / May 2, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the plan to form ETC Marketing Inc. ("ETC Marketing") in partnership with Third Coast Fulfillment LLC ("TCF"), to serve the new ENZC initiative...
Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.
NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC PINK:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the...
Source: https://incomestatements.info
Category: Stock Reports